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ABSTRACT

ARTICLE HISTORY

Human papillomavirus (HPV) causes >40,000 cancer diagnoses each year, yet vaccination rates remain low
because widespread implementation of strategies to increase vaccinations has not occurred. Behavioral
nudges have demonstrated efficacy in improving uptake of desired behaviors in health care settings but
have not been tested for increasing HPV vaccinations. We assessed the impact of an intervention
combining behavioral nudges with other proven strategies (i.e., assessment and feedback, provider
communication training) on HPV vaccination rates and parental satisfaction in four Midwestern pediatric,
outpatient practices. Practices were randomly assigned to receive either assessment and feedback or
assessment and feedback combined with vaccine communication training and behavioral nudges in the
form of vaccine commitment posters. Providers (n = 16) completed surveys regarding vaccine policies and
parents (n = 215) reported on their child’s vaccine history and satisfaction with the consultation. Three
practices increased HPV vaccination rates (1–10%); however, there was no statistically significant differ
ence by study arm. Most parents (M age 41.3; SD 8.1; 85% female, 68% White) indicated their child had
previously initiated the HPV vaccine series (61%) and 72% indicated receipt of an HPV vaccine during the
study visit. Concerns among HPV vaccine-hesitant parents (28%) included vaccine safety and believing the
vaccine is unnecessary (40%). Most parents were satisfied with their consultation. Practices in both
intervention groups increased vaccination rates. While some parents continue to harbor concerns
about vaccine safety and necessity, parents welcomed discussions about HPV and were satisfied with
their provider’s communication regardless of their vaccine decisions.
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Introduction
Every year 14 million Americans are infected with human
papillomavirus (HPV) and more than 44,000 are diagnosed
with HPV-related cervical, oropharyngeal, anal, penile, or vagi
nal cancer.1,2 While vaccines to prevent HPV infection have
been widely available for more than a decade, vaccine initiation
rates in the U.S. are only 69.9% for adolescent girls and 66.3%
for boys.3 Regional disparities also exist, with some
Midwestern states reporting HPV vaccination rates 6% lower
than the national average.3 HPV vaccination rates in the
U.S. lag behind other developed countries, like Australia
whose rates range from 76% to 80% for males and females.4
Effective strategies, including The Centers for Disease
Control and Prevention (CDC) AFIX (Assessment, Feedback,
Incentive and eXchange) quality improvement program and
high-quality provider recommendations that include presump
tive announcements, cancer prevention messaging, and urging
of same-day vaccination, have been effective in increasing HPV
vaccination rates.5–13 However, consistent implementation of
these strategies has not been realized with less than 50% of
parents receiving a high-quality HPV vaccine recommendation,
and some not receiving a recommendation at all.10 Behavioral
CONTACT Andrea Bradley-Ewing
abradleyewing@cmh.edu
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“nudges,” operationalized as poster-sized commitment displays,
have demonstrated success in improving antibiotic prescribing
and hand hygiene among providers in clinical care settings.14–17
Nevertheless, no studies to date have examined the potential
impact of behavioral nudges on HPV vaccination rates. This
pilot study examined the comparative effectiveness of an inter
vention that combined assessment and feedback with behavioral
nudges and provider communication training, to a single inter
vention of assessment and feedback to increase HPV vaccination
rates and assess parent satisfaction.

Methods
Procedures
Community-based practices affiliated with an integrated aca
demic pediatric network were invited to participate in the
study. Four practices in urban and suburban areas in
a Midwestern region of the United States with lower than
national average HPV vaccination rates participated.
Practices were matched on baseline HPV vaccination rates
(lower = <50% initiation vs higher performing = ≥50% initia
tion) and randomized to receive either the combined (C)
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intervention (assessment and feedback, provider communica
tion training, and behavioral nudges) or the single (S) inter
vention (assessment and feedback alone). One lower and one
higher performing practice was randomized to each arm.
Baseline and post-intervention vaccination rates were deter
mined through billing claims data submitted by each practice
through the Children’s Health Network (CHN) database admi
nistered by a local academic children’s hospital.
Participants
A convenience sample of parents or legal guardians (hereinto
referred to as parents) was recruited from each practice.
Parents were eligible to participate if they were aged 18 or
older, English speaking, and presented to one of the four
practices with a child aged 9–17 who had not completed the
HPV vaccine series. Data collection occurred from
October 2018 through September 2019. The study protocol
was approved by the hospital’s Institutional Review Board
(IRB approval # 00000134).
Measures
Data, including demographics, child’s vaccine history, and
parent’s thoughts about HPV vaccine and the visit were col
lected. The survey was self-administered after the parents’
consultation with a pediatric care provider. All responses
were collected and managed using REDCap electronic data
capture tools via tablet computers.18 Data collection activities
took approximately 5 minutes to complete.
Demographics
Demographic information collected included parents' age, gen
der, race education, and ethnicity. Additionally, parents were
asked demographic questions about their child (age, race,
gender, health insurance type).
Vaccine history
Ten items assessed adolescents’ prior vaccine history. Parents
were asked to indicate whether a health care provider ever
recommended tetanus-diphtheria-pertussis vaccine (Tdap/
“tetanus shot”), MCV (meningococcal conjugate vaccine/
“meningitis shot”) or HPV vaccines. Additionally, parents
were asked how old their child was when they received the
recommendation and whether their child received each
vaccine.
HPV vaccine intentions
Vaccine intentions were assessed by asking parents of children
who had not yet completed the HPV vaccine series to indicate
the likelihood that their child would receive an HPV vaccine
within the next 12 months using a 5-point Likert scale with
responses ranging from “not at all likely” to “very likely”.
Parents who indicated their child completed the vaccine series
that day were not asked about their future vaccine intentions.
To analyze future vaccine intentions, parents were classified as
HPV vaccine hesitant if they responded with “not too likely”,
“not likely at all”, or “not sure/don’t know”, whereas “very
likely” and “somewhat likely” responses were considered non-

hesitant. Parents who indicated it was unlikely their child
would receive an HPV vaccine in the future provided
a reason for their hesitation.
Satisfaction with provider
Parent satisfaction with the consultation was assessed with
the Engagement with Health Care Provider scale,19 a 13-item
scale developed to measure patient’s satisfaction with the
services offered by their providers. Reliability of the scale is
high (Cronbach’s alpha = .96).19 Parents were asked to indi
cate their level of satisfaction with their child’s health care
provider’s communication about vaccines as well as the over
all visit. Response options ranged from very satisfied to very
dissatisfied.
Analysis
Categorical frequencies were calculated with differences in
proportions compared using chi-square tests (Pearson’s and
Fisher’s exact, where appropriate). The Kruskal–Wallis test was
used to compare engagement scores across sites and across
arm.20 Unadjusted logistic regression models were run when
comparing the odds of HPV initiation and same-day vaccina
tions across sites and across arms. Quantitative analyses were
completed using Stata 14.2 software.21 Content analysis strate
gies were used to identify common themes in parents’ stated
reasons for why it was “not likely at all”, “not too likely”, or
“not sure/don’t know” if their child would receive an HPV
vaccine in the next 12 months.22 Using open coding proce
dures, two coders independently identified seven themes and
assigned parents’ response to one or more theme.
Disagreements between raters were resolved through discus
sion and consensus.

Results
Vaccination rates by practice
Three of the four practices evidenced an increase in HPV
vaccination rates and there was a statistically significant differ
ence by practice; however, there was no significant difference by
study arm (Figure 1. Baseline and Follow-up HPV Vaccination
Rates Practice Claims data). The two practices with the highest
baseline HPV vaccination rates (S1 and C2), evidenced a 3–10%
increase in HPV vaccine initiation rates at 12-month follow-up.
Practices with higher baseline vaccination rates had a significant
increase in HPV vaccination rates compared to practices with
lower baseline vaccination rates (p < .001). The second singleintervention practice (S2) had a slight increase (1%) while the
other combined intervention practice (C1) was relatively
unchanged. In addition to increased HPV vaccination rates, all
practices also showed an increase in Tdap and meningococcal
rates (0.8% to 12.1%) (Table 1).
Parents’ thoughts about HPV vaccines
Overall, 215 parents were enrolled in the study. Demographic
data were analyzed for all parents and patients (Table 2). Most
parents were, female (85%), White (68%), with a mean age of
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Figure 1. Baseline and Follow-up HPV Vaccination Rates (Practice Claims data).

Table 1. Baseline and Follow-up of Tdap and MCV Vaccination Rates (Practice
Claims data).
clinic
S1
S2
C1
C2
S1
S2
C1
C2

vaccine
Tdap
Tdap
Tdap
Tdap
MCV
MCV
MCV
MCV

baseline
86.6
57.1
71.3
72.9
84.5
79.6
72.5
86.1

post_period
88.3
69.2
73.4
74.2
87.6
83
75.1
86.9

change
1.7
12.1
2.1
1.3
3.1
3.4
2.6
0.8

41.34 years (SD = 8.05). More than half of the adolescent
patients were female (53%) and White (63%), with a mean
age of 12.15 years (SD = 1.68).
Vaccine history
When asked “Has a doctor or other health care provider ever
recommended your child receive the HPV vaccine?” 95% of
parents responded “yes.” However, the proportion of parents
that indicated their child had initiated the HPV vaccine series
(61%) was significantly lower when compared to Tdap (86%;
p < .001) and MCV (69%; p < .001). Many parents were unsure
of their child’s prior vaccine history, including 2% who were
uncertain about prior HPV vaccination, and 17% who were
unsure of previous MCV vaccination. However, 72% of parents
indicated their child received an HPV vaccine during the study
visit (Table 3).
Intentions for future HPV vaccination
Most parents whose child had not completed the vaccine series
(70%) indicated their child would likely receive an HPV vac
cine within the next 12 months. Nearly 9% of parents were
uncertain about their future vaccine intentions. Vaccine hesi
tancy was similar in the combined and single-intervention

Table 2. Parent and patient Demographics.
Parent age – mean (sd)
Female parent – n (%)
Hispanic parent
Parent race
African American
White
Other
Parent education
Some high school
HS degree or GED
Post HS training
Undergraduate degree
Graduate degree
Other/unknown
Child age – mean (sd)
Insurance – n(%)
Private
Medicaid/Medicare
Other/None
Female child
Hispanic child
Child race
African American
White
Other

41.3 (8.1)
169 (85.4%)
7 (3.6%)
55 (27.8%)
134 (67.7%)
9 (4.6%)
6 (3.0%)
22 (11.1%)
72 (36.4%)
58 (29.3%)
35 (17.7%)
5 (2.5%)
12.2 (1.7)
135 (68.2%)
58 (29.3%)
5 (2.5%)
105 (53.0%)
14 (7.1%)
54 (27.3%)
125 (63.1%)
19 (9.6%)

arms (27% vs. 33%; p = .51). Vaccine hesitation varied across
sites, from 19% to 38%, although these differences were not
significant (p = .18).
Reasons for why it was “not likely at all”, “not too likely”,
or “not sure/don’t know” that their child would receive an
HPV vaccine in the next 12 months were provided by 60
parents. Reasons included parental concerns about vaccine
safety (30%), beliefs that the vaccine was unnecessary (15%),
and because their child was not sexually active (20%). Less
common reasons for hesitancy regarding future HPV vaccine
uptake included lack of provider recommendation (2%), no
requirement for school entry (5%), lack of insurance or costs
of vaccination (2%), and limited knowledge that HPV could
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Table 3. Parent reported HPV vaccination uptake.

a

Frequency

Percent

Odds ratio

p-value

Has your child ever received an HPV shot? a
Yes
S1
S2
C1
C2
Single Intervention (S)
Combined Intervention (C)

95% CI

23
34
28
42
57
70

79.3%
53.1%
59.6%
68.9%
61.3%
64.8%

3.38
-ref1.30
1.95
-ref1.16

0.02
–
0.50
0.07
–
0.61

1.22, 9.42
–
0.61, 2.79
0.94, 4.05
–
0.66, 2.07

Child received an HPV shot today?
Yes
S1
S2
C1
C2
Single Intervention (S)
Combined Intervention (C)

27
39
34
49
66
83

90.0%
59.1%
68.0%
80.3%
68.8%
74.8%

6.23
-ref1.47
2.83
-ref1.35

0.01
–
0.33
0.01
–
0.34

1.72, 22.63
–
0.68; 3.18
1.27; 6.29
–
0.73, 2.48

Parental reports of ‘unknown’ whether the vaccine was administered were excluded

cause cancer (2%) and other reasons (e.g. waiting until older
to vaccinate-25%).
Parent satisfaction
Most parents were satisfied with the provider’s communication
(≥96%), as well as their overall consultation (≥96%). There was
no difference in satisfaction between parents of patients who
received a same-day HPV vaccination and those who did not
(p = .20). Both parents of children who received a vaccine at the
visit, and those who did not felt informed about their decision
(p = .19) and that their decision was best for their child
(p = .69). There was also no difference in satisfaction scores
between clinic sites (p = .58) or study arms (p = .42).

Discussion
Three practices evidenced an increase in HPV vaccination rates
from baseline to study end. This result was somewhat expected
as all four sites received an active intervention. However,
despite being randomized to different study arms, the two
practices with similarly high baseline vaccination rates had
the highest increase in post-intervention vaccination rates.
This suggests the impact of interventions may be moderated
by clinic policies, procedures, and culture. For example, exit
interviews with providers revealed that practices with higher
baseline vaccination rates had formal policies requiring every
member of the health care team to be aware of a patient’s
vaccine status prior to their well-child visit. Other policies
included recommending and administering vaccines to eligible
patients during any visit (e.g. sick visit, sibling’s well-visit), and
excusing parents from the practice who choose not to vaccinate
their children (e.g., Tdap and MCV). We also noted that
practices with an increase in HPV vaccination rates also had
increased rates of Tdap and MCV vaccines. This result con
firms results found in previous studies5,9–13 that suggest par
ents are more likely to agree to initiate or complete the HPV
vaccine series when bundled with other adolescent vaccines.
Additionally, some of the sites received CDC and industrysponsored HPV vaccine promotional items and one singleintervention site decided to appoint a vaccine coordinator

shortly after their baseline visit to improve their early child
hood and adolescent vaccination rates.
In addition to practice policies, practices with higher base
line and post-intervention HPV vaccination rates tended to be
smaller (e.g., 4 or fewer primary care providers), located in
suburban communities, and maintained a more stable patient
population, increasing the likelihood that the patient’s vaccine
history was known to clinic staff and patients would likely
return for follow-up care. During parent recruitment activities,
research coordinators noted clinic staff often had a longstanding relationship with patients and families (5 or more
years) and often provided care for more than one member of
the family. Research suggests that parent-provider communi
cation and rapport may impact parent’s willingness to follow
the advice of their child’s health care provider.23 Additionally,
dissemination of interventions may be more effective in smal
ler practices with centralized communication channels and
a vaccine champion who sets the tone for the practice.
Most parents received HPV vaccine recommendations from
their child’s health care providers; however, nearly 40% elected
not to vaccinate their child and baseline HPV vaccination rates
were significantly lower than those of other adolescent recom
mended vaccines. This suggests that in addition to training
providers to make strong HPV vaccine recommendations
that are bundled with other adolescent vaccines, there is
a need to incorporate additional parent-focused educational
tools to address concerns and dispel myths about HPV vac
cines. Specifically, future interventions should highlight HPV
vaccine safety, cancer prevention, and a rationale for the
recommended vaccine initiation age (most hesitant parents
[65%] expressed concerns that the vaccine was unsafe or not
necessary or appropriate for their child).
A majority of parents in this study were satisfied with the
communication from their child’s health care provider. These
results are similar to previous studies9–13 that indicate most par
ents do not object to HPV vaccine discussions. It is important to
note that while most parents indicated their child either received
an HPV vaccine during the current visit or indicated future
intentions to initiate the series, 28% of parents in the current
study indicated vaccine hesitancy. Additionally, 15 parents who
indicated their child had not initiated the HPV vaccine series
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during the current visit reported their child would likely initiate
the series within the next 12 months. The median age of these
children was 12, raising the possibility that some parents may still
prefer to delay HPV vaccination until their child is older.
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Limitations
This study has several limitations. Parents were asked if they had
received an HPV vaccine recommendation and their child’s
previous vaccine status, which is subject to recall bias.
However, we attempted to mitigate this by providing the survey
immediately following the current visit in which vaccines were
discussed. We also do not have data on parents who declined to
participate, and it is possible that their survey responses to
vaccination and satisfaction with the visit may have been differ
ent than those that agreed to participate. However, a low percen
tage of parents (4% of those approached) declined to participate.
Finally, while providers in the combined intervention arm were
trained to provide a high-quality vaccine recommendation (e.g.,
presumptive, bundled with other vaccines and indicating a sense
of urgency, cancer prevention, and importance), we did not
assess whether parents received recommendations that incorpo
rated these elements of a high-quality recommendation. This
could partially contribute to the lack of statistically significant
difference in vaccination rates between study arms, as previous
studies suggest that parents who receive high-quality recommen
dations are more likely to vaccinate their child than those who
receive lower quality recommendations.10 It is unclear from our
results if increases in vaccinations displaced other vaccinations.
For example, people vaccinated at our clinics may have otherwise
received vaccinations at pharmacies or other clinics. However,
prior work on vaccinations using nudges has failed to identify
displacement as the cause of the vaccination effect.24
Conclusion
This study showed that parents are willing to discuss HPV
vaccination with their child’s health care provider and report
high levels of satisfaction regardless of their vaccination deci
sions. This should encourage providers to initiate conversa
tions about HPV vaccines with all their eligible patients.
Additionally, clinics with a higher baseline HPV vaccination
rate were more likely to increase their vaccination rates regard
less of intervention arm. This suggests that the presence of
a recommendation alone is not adequate to achieve high rates
of vaccination, but other factors (i.e. the strength and quality of
the recommendation) may impact parent’s vaccine decisions.
A future study will examine the impact of combining all ele
ments of high-quality vaccine recommendations (e.g. pre
sumptive announcement, importance, cancer prevention,
urgency, & bundling) on HPV vaccination rates, parent’s vac
cine decisions, and visit satisfaction.
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